VITRASERT Drug Patent Profile

When do Vitrasert patents expire, and when can generic versions of Vitrasert launch?

Vitrasert is a drug marketed by Bausch And Lomb and is included in one NDA.

The generic ingredient in VITRASERT is ganciclovir. There are twenty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ganciclovir profile page.

Summary for VITRASERT

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for VITRASERT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb	VITRASERT	ganciclovir	IMPLANT;IMPLANTATION	020569-001	Mar 4, 1996		DISCN	No	No

International Patents for VITRASERT

See the table below for patents covering VITRASERT around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	1419792
Australia	660012
European Patent Office	0577646	SYSTEMES D'ADMINISTRATION DE MEDICAMENTS A LIBERATION PROLONGEE (SUSTAINED RELEASE DRUG DELIVERY DEVICES)
Austria	171617
Denmark	0577646
Spain	2366573

Supplementary Protection Certificates for VITRASERT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0694547	03C0003	France		PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920
0694547	2002/028	Ireland		PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
0694547	SPC/GB02/027	United Kingdom		PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425
0694547	C300071	Netherlands		PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920

Last updated: February 10, 2026

What Is the Current Market and Investment Outlook for VITRASERT?

VITRASERT, a sustained-release formulation of ganciclovir, is marketed primarily for the treatment of cytomegalovirus (CMV) retinitis. It is approved in select markets, notably the United States under the trade name Vitrasert, with limited availability elsewhere. The drug’s market presence is constrained by its approval status, manufacturing complexity, and competition from newer therapies, including intravitreal injections of prefilled implants and systemic antivirals. Investment prospects are influenced by regulatory status, pipeline developments, and evolving treatment protocols.

What Are the Key Market and Regulatory Factors Influencing VITRASERT?

VITRASERT operates under specific regulatory constraints, with approval primarily for intravitreal use in CMV retinitis in immunocompromised patients, such as those with AIDS. Its approval in the U.S. (by the FDA) was based on early 1990s submissions, with no recent label extensions. The drug’s manufacturing complexity, involving a biodegradable implant, affects margins and market penetration.

Enhanced competition includes foscarnet, valganciclovir, and newer intravitreal options like the port delivery system for ranibizumab, which, although used for different indications (age-related macular degeneration), highlight advancements in drug delivery systems impacting similar therapeutic areas.

Regulatory risks include potential obsolescence due to newer agents demonstrating improved efficacy, safety, or delivery convenience. Any pending or recent regulatory decisions can significantly alter investment outlooks. The patent landscape, although not straightforward, influences market exclusivity periods; VITRASERT’s original patent expired decades ago, opening the market to generics where approved.

How Do the Revenue and Market Penetration Fundamentals Look?

VITRASERT margins are constrained by manufacturing costs and limited global licensing. The drug's revenue remains modest, primarily from the U.S. [1]. The prevalence of CMV retinitis has declined due to HAART (highly active antiretroviral therapy) in HIV-positive populations, reducing the total addressable market.

The current market size is estimated near USD 50–70 million annually in the U.S., with potential for minimal growth unless new indications or formulations are approved. External factors such as advances in systemic oral antivirals and sustained-release implants for different indications threaten market share.

Price points for VITRASERT historically hovered around USD 10,000 per implant per treatment course, with costs for manufacturing and clinical administration representing a substantial portion of expenditure. Limited use due to invasive administration and side effect profiles inhibits broader market adoption.

What Is the Pipeline and Development Strategy for VITRASERT?

No recent development activities or pipeline extensions for VITRASERT are publicly documented. The original formulation remains the sole marketed product with no current plans for reformulation or new indications. The company’s strategic focus appears to have shifted toward newer, longer-acting therapies, potentially deprioritizing VITRASERT’s future.

Other drug development efforts in this space include intravitreal corticosteroids and viral vector-based therapies, which may threaten to displace VITRASERT if they demonstrate superior efficacy or fewer side effects.

What Are the Investment Risks and Opportunities?

Risks:

• Market decline: Reduced incidence of CMV retinitis in HIV-positive populations limits expansion.
• Regulatory obsolescence: Lack of recent approvals or updates increases risk of market withdrawal.
• Manufacturing challenges: Complex implant production increases costs and limits scalability.
• Competition: Advances in systemic antivirals and alternative delivery methods pose a significant threat.

Opportunities:

• New indications: Potential for adjunct use in other CMV-related conditions, pending approval.
• Technological upgrades: Reformulation to improve administration or efficacy could revive interest.
• Partnerships: Licensing or co-development agreements could expand market reach.

What Are the Key Takeaways?

VITRASERT remains a niche product with limited growth prospects. It benefits from established efficacy for CMV retinitis but faces obsolescence due to evolving treatment paradigms and technological competition. The limited market, manufacturing costs, and regulatory stagnation constrain investment value. Future opportunities hinge on innovation, additional indications, or partnerships, none of which are currently confirmed.

FAQs

1. Is VITRASERT still approved for use in the U.S.?
Yes, it remains marketed for CMV retinitis, but no recent regulatory updates suggest active expansion or new indications.

2. Are there any new formulations in development?
No publicly available data indicates ongoing reformulation or new versions.

3. How does its efficacy compare to newer therapies?
VITRASERT’s efficacy was established in earlier trials; newer systemic antivirals and sustained-release implants offer comparable or improved outcomes with less invasive administration.

4. Could VITRASERT benefit from regulatory re-approval for expanded indications?
This is unlikely without new clinical data; the market size and regulatory hurdles pose significant barriers.

5. What is the likely future of VITRASERT in the global market?
The outlook points to a marginal role unless technological or clinical breakthroughs occur, given the declining incidence of CMV retinitis in developed markets.

---

References

[1] Company filings, market reports, and publicly available FDA approval documents.